Oxotremorine suppresses thalamocortical oscillations via thalamic muscarinic acetylcholine receptors.
We investigated whether the local intrathalamic infusion of a muscarinic acetylcholine receptor agonist (oxotremorine) at either the reticular nucleus of thalamus (NRT) or the ventroposteromedial nucleus of thalamus (VPM) suppresses thalamocortically generated neocortical high-voltage spindles (HVSs). In addition, we studied whether the intracerebroventricular (ICV) infusion of a selective muscarinic M2 acetylcholine receptor antagonist (methoctramine) could block the suppression of HVSs induced by either systemic (IP) administration of an anticholinesterase drug [tetrahydroaminoacridine (THA)] or ICV infusion of oxotremorine in rats. Intrathalamic administration of oxotremorine at 3 and 15 microg in the NRT, and at 15 microg in the VPM suppressed HVSs. ICV oxotremorine at 30 and 100 microg and IP THA at 3 mg/kg decreased HVSs. ICV methoctramine at 100 microg increased HVSs and completely blocked the decrease in HVSs produced by oxotremorine 100 microg and THA 3 mg/kg. The results suggest that activation of muscarinic M2 acetylcholine receptors in thalamic nuclei (NRT and VPM) can suppress thalamocortical oscillations and that ICV or systemically administered drugs that activate either directly (oxotremorine and methoctramine) or indirectly (THA) the muscarinic M2 acetylcholine receptors may modulate neocortical HVSs via the thalamus.
Puoliväli
J
J
Department of Neuroscience and Neurology, University of Kuopio and Kuopio University Hospital, Finland. puolival@uku.fi
Jäkälä
P
P
Koivisto
E
E
Riekkinen
P
P
D000818:Animals; D003959:Diamines / Q000008:administration & dosage*; D004347:Drug Interactions; D004569:Electroencephalography / Q000187:drug effects*; D008297:Male; D018721:Muscarinic Agonists / Q000008:administration & dosage*; D010095:Oxotremorine / Q000008:administration & dosage*; D010276:Parasympatholytics / Q000008:administration & dosage*; D051381:Rats; D013619:Tacrine / Q000008:administration & dosage*; D013787:Thalamic Nuclei / Q000187:drug effects*
D003959:Diamines; D018721:Muscarinic Agonists; D010276:Parasympatholytics; D013619:Tacrine; D010095:Oxotremorine; C054938:methoctramine